385844-06-4

Upstream product

• 106000-09-3 1-<2-Chloro-2-(4-fluorophenyl)ethyl>-4-ethoxycarbonylpiperazine 
• 89011-47-2 ethyl 4-[2-(4-fluorophenyl)-2-hydroxyethyl]piperazine-1-carboxylate hydrochloride 
• 932028-04-1 1-[2-(4-fluorophenyl)-2-(4-isopropylpiperazin-1-yl)ethyl]-4-[4-(2-methoxy-1-naphthyl)butanoyl]piperazine 
• 552885-52-6 ethyl 4-[2-(4-fluorophenyl)-2-(4-isopropylpiperazin-1-yl)ethyl]piperazine-1-carboxylate 
• 686710-22-5 (+/-)-1-[1-(4-fluorophenyl)-2-piperazin-1-ylethyl]-4-isopropylpiperazine 
• 385844-35-9 1-[2-(4-Fluorophenyl)-2-(4-isopropylpiperazino)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine 

Relevant academic research and scientific papers

Structure-activity relationships of novel piperazines as antagonists for the melanocortin-4 receptor

During the investigation of antagonists for the MC4 receptor, we found that 10ab having a naphthyl group showed almost the same binding affinity for the MC4 receptor as that of the lead compound 1 with a benzoyl group. We also developed a new type of compounds, namely, bis-piperazines, and found that the bis-piperazines 10 exhibited a high affinity for the MC4 receptor. In particular, (-)-10bg exhibited the highest affinity for the MC4 receptor with an IC50 value of 8.13 nM. In this paper, we present the design, synthesis, and structure-activity relationships of the novel bis-piperazines as MC4 receptor antagonists.

Remedial agent for anxiety neurosis or depression and piperazine derivative

There are provided a therapeutic preparation for anxiety neurosis or depression which comprises a MC4 receptor antagonist as an effective ingredient; and a piperazine derivative represented by Formula [1]: [wherein Ar1 is a phenyl gr